Results from APOLLO, a randomized phase III study, indicated that a "near-chemotherapy free treatment of arsenic trioxide in combination with all-trans retinoic acid plus low-dose idarubicin significantly improved outcomes of patients with newly diagnosed, high-risk acute promyelocytic leukaemia." A median follow-up of 37 months indicated that 2-year event free survival was 88% in patients receiving all-trans retinoic acid and arsenic trioxide vs. 71% in patients receiving all-trans retinoic acid plus anthracycline-based chemotherapy.
To read more about the APOLLO study, click here.
Sources mentioned:
- Platzbecker U, Adès L, Montesinos P, et al. on behalf of the SAL, AMCL-CG, AML-SG, OSHO, PETHEMA, HOVON and GIMEMA study groups. Arsenic Trioxide and All-Trans Retinoic Acid Combination Therapy for the Treatment of High-Risk Acute Promyelocytic Leukemia: Results From the APOLLO Trial . JCO; Published online 18 August. DOI: https://doi.org/10.1200/JCO-25-00535
- Iland HJ. APOLLO: Optimizing the Treatment of High-Risk Acute Promyelocytic Leukemia With All-Trans Retinoic Acid and Arsenic Trioxide While Minimizing the Role of Chemotherapy . JCO; Published online 18 August 2025. DOI: https://doi.org/10.1200/JCO-25-01496
High-risk APL is one of the clearest examples of differentiation therapy changing a once-feared diagnosis, and arsenic trioxide with ATRA continues to refine how little conventional chemotherapy some patients may need. Early mortality and differentiation syndrome still demand respect, so protocol discipline matters as much as the drugs. Frontline questions like this are often covered in discussions led by rohit gosain, especially where trial regimens meet everyday haematology care.
ReplyDeleteA 17-point event-free survival gap at two years, 88% versus 71%, is the kind of margin that rewrites treatment protocols — APOLLO makes the "near-chemotherapy free" label feel deserved for high-risk APL. The multicentre scale across SAL, GIMEMA, and the other study groups gives the result real-world weight too. It is remarkable how far differentiation therapy has come since the days when high-risk APL was such a feared diagnosis.
ReplyDelete